drugset

Drugs / LP-300

Follow last change Jun 2026 re-read 3 minutes ago

LP-300

Developed for: lung adenocarcinoma
Investigated by: Lantern Pharma Inc.

Trials 1

today NCT05456256 · Ph 2

2024202520262027

Phase	Registry id	Dates	Indication	Sponsor	Status	Outcome
Phase 2	NCT05456256	Mar 2023 → Dec 2026 expected	lung adenocarcinoma	Lantern Pharma Inc.	Recruiting	No outcome recorded

Press releases naming this drug 9 releases

Date	Issuer	Release
2026-06-02	Lantern Pharma Inc.	Lantern Pharma Reports HARMONIC™ Data Showing LP-300 Progression-Free Survival Benefit Deepens with Treatment Duration in EGFR Exon 21 L858R Lung Cancer lanternpharma.com ↗
2026-05-19	Lantern Pharma Inc.	Lantern Pharma Announces Successful Outcome of FDA Type C Meeting Request for HARMONIC™ Phase 2 Trial of LP-300 in Never-Smokers with NSCLC lanternpharma.com ↗
2026-04-20	Lantern Pharma Inc.	Emerging Data for Lantern Pharma’s Investigational Drug LP-300 Demonstrates 8.3-Month Median Progression-Free Survival in Patients with EGFR L858R Lung Cancer After Targeted Therapy Failure — With No Added Toxicity lanternpharma.com ↗
2025-07-31	Lantern Pharma Inc.	Lantern Pharma Completes Targeted Enrollment for Lung Cancer Phase 2 Harmonic™ Clinical Trial in Japan for LP-300 lanternpharma.com ↗
2024-12-09	Lantern Pharma Inc.	Lantern Pharma Announces First Patient Enrolled in Taiwan for Phase 2 HARMONIC™ Clinical Trial of LP-300 in Never-Smoker NSCLC Patients lanternpharma.com ↗
2024-11-19	Lantern Pharma Inc.	Lantern Pharma Announces First Patient Dosed in Japan for The Expansion Cohort in The Phase 2 HARMONIC™ Clinical Trial of LP-300 in Never-Smoker NSCLC Patients lanternpharma.com ↗
2023-03-28	Lantern Pharma Inc.	Lantern Pharma Announces First Patient Dosed in the Phase 2 Study, Harmonic™, for LP-300 in Never Smokers with Advanced Non-Small Cell Lung Cancer lanternpharma.com ↗
2022-10-20	Lantern Pharma Inc.	Lantern Pharma Announces Issuance of New Patent that Strengthens Patent Portfolio for Cancer Drug Candidate LP-300 lanternpharma.com ↗
2022-07-14	Lantern Pharma Inc.	Lantern Pharma Receives FDA Authorization to Initiate its Phase 2 Clinical Trial, Harmonic™, for LP-300 in Never Smokers with Non-Small Cell Lung Cancer lanternpharma.com ↗

Evidence & citations 1 cited value

Every value below carries the sentence it was read from. 1 source stands behind the page.

Field	Value	Cited text
Known as	LP-300	ClinicalTrials.gov intervention name — accepted as the source's own label NCT05456256 ↗